Telix Group inks deal with ININ to boost prostate imaging technology
Category: #health  By Pankaj Singh  Date: 2019-01-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Telix Group inks deal with ININ to boost prostate imaging technology

Telix Pharmaceuticals Limited, through its wholly-owned subsidiary Advanced Nuclear Medicine Ingredients SA (ANMI), has recently announced that it has entered into an agreement with Mexico’s Instituto Nacional de Investigaciones Nucleares (ININ) and completed the in-licensing of ININ’s 99mtechnetium-EDDA/HYNIC-Lys (NaI)-Urea-Glu (99mTc-iPSMA). Apparently, the product is an innovative clinical-stage radiopharmaceutical for prostate cancer imaging.

According to Telix, Single Photon Emission Computed Tomography, termed as SPECT, is widely deployed nuclear medicine imaging procedure, particularly for managing cancer, being an alternative to the Positron Emission Tomography or PET approach already being developed by ANMI. SPECT, even though similar to PET with regards to radioactive trace usage and gamma ray detection, is the dominant nuclear imaging modality in cancer management due to less availability of PET/CT worldwide.

Sources close to the matter informed that the team of ININ and its partners have been able to clinically evaluate 99mTc-iPSMA with SPECT/CT, the results of which show highly sensitive detection of lesions in prostate cancer. There is considerable commercial and clinical potential of the product for evaluating both primary disease and metastases in regions where extensive PET infrastructure is not present.

Reportedly, 99mTc-iPSMA has strong international patent protection in several commercial markets. 99mTc-iPSMA has been developed as result of world-class research performed by innovative ININ research group from the National Laboratory on Research and Development of Radiopharmaceuticals (LANIDER), sources mentioned. The group has substantial experience in the nuclear medicine field. 

Through scientific partnerships with the National Laboratories of the National Council of Science and Technology (CONACyT) and Mexican National Institute of Cancerology (INCan), LANIDER group maintains numerous international and national collaborations.

For the record, Telix is headquartered in Melbourne and has operations internationally in the U.S., Japan and EU. Telix’s license agreement with ININ represents a worldwide agreement and also includes a partnership for manufacturing the product.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...